Daiwa Securities Group Inc. Lowers Holdings in Abbott Laboratories (ABT)

Daiwa Securities Group Inc. lessened its stake in Abbott Laboratories (NYSE:ABT) by 3.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 163,609 shares of the healthcare product maker’s stock after selling 6,043 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Abbott Laboratories were worth $12,002,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. FCG Advisors LLC acquired a new stake in Abbott Laboratories in the 3rd quarter valued at about $242,000. Welch Group LLC increased its position in Abbott Laboratories by 9.2% in the 3rd quarter. Welch Group LLC now owns 18,088 shares of the healthcare product maker’s stock valued at $1,327,000 after acquiring an additional 1,531 shares in the last quarter. Strategy Asset Managers LLC acquired a new stake in Abbott Laboratories in the 3rd quarter valued at about $3,237,000. Private Advisor Group LLC increased its position in Abbott Laboratories by 15.4% in the 3rd quarter. Private Advisor Group LLC now owns 156,531 shares of the healthcare product maker’s stock valued at $11,483,000 after acquiring an additional 20,856 shares in the last quarter. Finally, WealthTrust Axiom LLC acquired a new stake in Abbott Laboratories in the 3rd quarter valued at about $209,000. Hedge funds and other institutional investors own 72.30% of the company’s stock.

In related news, SVP Jaime Contreras sold 64,268 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, August 29th. The shares were sold at an average price of $66.84, for a total transaction of $4,295,673.12. Following the transaction, the senior vice president now owns 125,471 shares of the company’s stock, valued at approximately $8,386,481.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brian J. Blaser sold 58,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, September 20th. The stock was sold at an average price of $68.79, for a total transaction of $4,003,578.00. Following the transaction, the insider now directly owns 184,918 shares in the company, valued at approximately $12,720,509.22. The disclosure for this sale can be found here. Insiders have sold a total of 203,297 shares of company stock worth $14,018,743 in the last three months. 0.74% of the stock is owned by insiders.

Several research firms have weighed in on ABT. Royal Bank of Canada restated a “buy” rating and issued a $70.00 price objective on shares of Abbott Laboratories in a research report on Thursday, July 19th. BTIG Research reaffirmed a “hold” rating on shares of Abbott Laboratories in a research note on Thursday, October 18th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $80.00 target price on shares of Abbott Laboratories in a research note on Thursday, October 18th. Stifel Nicolaus raised their target price on shares of Abbott Laboratories from $71.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, July 19th. Finally, Raymond James raised their target price on shares of Abbott Laboratories from $72.00 to $77.00 and gave the company an “outperform” rating in a research note on Monday, September 24th. One analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $75.22.

Shares of NYSE ABT opened at $72.79 on Friday. The stock has a market capitalization of $127.33 billion, a PE ratio of 25.80, a price-to-earnings-growth ratio of 2.15 and a beta of 1.39. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.13 and a current ratio of 1.42. Abbott Laboratories has a 1 year low of $54.32 and a 1 year high of $74.15.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, October 17th. The healthcare product maker reported $0.75 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.75. The company had revenue of $7.66 billion for the quarter, compared to analyst estimates of $7.65 billion. Abbott Laboratories had a net margin of 2.91% and a return on equity of 16.05%. The company’s revenue for the quarter was up 12.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.66 EPS. Analysts expect that Abbott Laboratories will post 2.89 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 15th. Investors of record on Monday, October 15th will be paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 1.54%. The ex-dividend date is Friday, October 12th. Abbott Laboratories’s payout ratio is 44.80%.

TRADEMARK VIOLATION NOTICE: “Daiwa Securities Group Inc. Lowers Holdings in Abbott Laboratories (ABT)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/11/10/daiwa-securities-group-inc-lowers-holdings-in-abbott-laboratories-abt.html.

Abbott Laboratories Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Recommended Story: Consumer behavior in bull markets

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply